The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
O'Sullivan, Jennifer M., Hamblin, Angela, Yap, Christina, Fox, Sonia, Boucher, Rebecca, Panchal, Anesh, Alimam, Samah, Dreau, Helene, Howard, Kieran, Ware, Pauline, Cross, Nicholas C.P., McMullin, Mary Frances, Harrison, Claire N., Mead, Adam J.
Published in Blood (05.12.2019)
Published in Blood (05.12.2019)
Get full text
Journal Article
Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study
O'Sullivan, Jennifer, Hamblin, Angela, Panchal, Anesh, Yap, Christina, Fox, Sonia, Alimam, Samah, Dreau, Helene Marie-Pierre, Howard, Kieran, Ware, Pauline, Baker, Samantha, Cross, Nicholas C.P., McMullin, Mary Frances, Harrison, Claire N., Mead, Adam J.
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article